KORU Medical Systems Names New CEO

KORU Medical Systems Inc. will welcome a new leader this summer.

President/CEO Linda Tharby plans to retire on June 30, after spending five years in the corner office. She will be succeeded by Chief Commercial Officer (CCO) Adam Kalbermattenas, effective July 1. Tharby will remain on the Board of Directors and serve in an advisory capacity through the end of the year to support the leadership succession plan.

“Adam is the right leader to guide KORU into its next phase of growth. From day one, it was clear he brought the strategic vision, operational discipline, and leadership needed to take on a larger role as the company continues to grow,” KORU Medical Board Chair John Fletcher commented. “On behalf of the Board, I want to thank Linda for her many contributions to KORU and for her leadership in helping build the strong foundation we have today. We are pleased that she will remain engaged as a director and advisor during the transition. With Adam at the helm, supported by an experienced leadership team and a proven strategy, we believe KORU is well-positioned to continue advancing its growth and delivering long-term value for shareholders.”

Under Tharby’s leadership, KORU Medical experienced a significant transformation, doubling its recurring patient base to more than 55,000 patients, expanding its international footprint, and broadening the Freedom infusion platform beyond immunoglobulin to new drug classes. During her tenure, the company delivered consistent revenue growth, achieved profitability, and established KORU Medical as a recognized market leader.

“Serving as chief executive officer of KORU has been the highlight of my career, and I am proud of what our team has accomplished together,” Tharby said. “We have built a stronger, more scalable business with a clear strategy and a leadership position with significant potential in the subcutaneous drug delivery business. Retiring is a personal decision as I prepare for my next chapter in life, and I do so with great confidence in the company’s future. Adam is the right leader for this next phase of growth, and I look forward to supporting him and the executive team as a board member through the transition.”

Kalbermatten joined KORU Medical last year as CCO, bringing to the position more than 20 years of experience in the medical device and pharmaceuticals industries. Before he was hired at KORU, he served as vice president and general manager of Advanced Drug Delivery Systems at Becton Dickinson where he led growth initiatives across the injectable drug delivery platform. Prior to Becton Dickinson, he was CEO of ZebraSci, a specialized provider of drug-device combination product development services; there, he led an effective turnaround and growth strategy that resulted in the company’s successful acquisition.

“I am honored by the trust that the Board has placed in me and excited to lead KORU Medical through its next stages of continued growth,” Kalbermatten stated. “KORU has built a strong foundation with differentiated technology, a compelling strategy, and a team committed to improving the patient experience. My focus will be on accelerating our growth, strengthening our leadership in subcutaneous drug delivery, and executing our strategic priorities to create long-term value for patients, customers, and shareholders. I am grateful to Linda for her leadership in establishing this foundation and look forward to building on that momentum as we continue advancing KORU’s mission.”

KORU Medical Systems develops, manufactures, and commercializes patient-centric large volume subcutaneous infusion solutions. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60 and FreedomEDGE Syringe Infusion Drivers, Precision Flow Rate Tubing, and HigH-Flo Subcutaneous Safety Needle Sets. The Freedom System, which received its first U.S. Food and Drug Administration clearance in 1994, is used for home self-administration by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories.